Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549365 | 1.00 | AAK1 (0.38) | AAK1TRPA1PPARGPPARACTSS | |
| SCHEMBL20549464 | 0.88 | AAK1 (0.38) | AAK1TRPA1PPARGPPARACTSS | |
| SCHEMBL20549465 | 0.88 | AAK1 (0.38) | AAK1TRPA1PPARGPPARACTSS | |
| SCHEMBL20549488 | 0.71 | AAK1 (0.38) | AAK1TRPA1CTSK | |
| SCHEMBL9404273 | 0.70 | MTNR1A (0.64) | PPARGPPARACTSSCTSKMTNR1A | |
| SCHEMBL8910228 | 0.70 | MTNR1A (0.64) | PPARGPPARACTSSCTSKMTNR1A | |
| SCHEMBL20471936 | 0.67 | AAK1 (0.49) | AAK1TRPA1CTSK | |
| SCHEMBL20549533 | 0.66 | MAOA (0.37) | — | |
| SCHEMBL20549530 | 0.66 | MAOA (0.37) | — | |
| SCHEMBL17041316 | 0.66 | AAK1 (0.48) | AAK1TRPA1CTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | AAK1 4067/4885TRPA1 4156/4885PPARG 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.